TLR1 and acute myeloid leukemia: In the AML-VAC-XS15-01 study we apply an innovative immune stimulator adjuvant formulation based on the TLR1/2 agonist XS15 that has already proven safety and tolerability as well as potent T cell activation in clinical trials [NCT04546841 (25), NCT04954469 (26)].